

Supplementary Table 2. Sensitivity Analyses for Change for MONARCH Primary Endpoint

	Adalimumab 40 mg q2w (n=185)	Sarilumab 200 mg q2w (n=184)	P value
Sensitivity analysis 1*			
DAS28-ESR, week 24			
Mean (SD)	4.5 (1.4)	3.5 (1.5)	
LS mean change from baseline (SE)	-2.2 (0.1)	-3.2 (0.1)	<0.0001
Sensitivity analysis 2†			
DAS28-ESR, week 24			
Mean (SD)	4.4 (1.3)	3.3 (1.3)	
LS mean change from baseline (SE)	-2.3 (0.1)	-3.3 (0.1)	<0.0001

*Included all data, including assessments made after permanent treatment discontinuation. All patients were requested to return for week 24 assessments even if they previously discontinued treatment.

†All data after treatment discontinuation or adalimumab (or matching placebo) dose increase were set to missing, and a multiple imputation approach (assuming missing at random) was used.

DAS28-ESR, 28-joint disease activity score using erythrocyte sedimentation rate; LS, least squares; q2w, every 2 weeks; SD, standard deviation; SE, standard error.